Plus   Neg

Sanofi Brain-penetrant BTK Inhibitor Meets Primary Endpoint Of Phase 2 Trial

Sanofi (SNYNF,SNY) said that brain-penetrant Bruton's tyrosine kinase or BTK inhibitor met primary endpoint of Phase 2 trial in relapsing multiple sclerosis.

The company noted that its BTK inhibitor will potentially be first disease-modifying therapy to address sources of multiple sclerosis damage in the brain.

The company plans to initiate four Phase 3 clinical trials in relapsing and progressive forms of multiple sclerosis.

Sanofi obtained global rights to develop and commercialize BTK inhibitor under a license agreement with Principia Biopharma.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Lowe's (LOW) is temporarily increasing wages of its employees. The latest move by the hardware retailer is to help its employees cope with the economical effects caused by the ongoing COVID-19 pandemic. The company has hiked salary by $2 per hour for all full-time, part-time, and seasonal hourly associates,... Amazon.com Inc. (AMZN) Founder and CEO Jeff Bezos is donating $100 million to food banks across the U.S. to support poor people who cannot afford food during this coronavirus crisis. Bezos made a $100 million gift to Feeding America, one of the largest U.S. nonprofit focused on food security. Feeding... Facebook on Thursday shared an update on its $100 million small-business grants program announced in March, saying that it will provide $40 million in grants to 10,000 U.S. small businesses that were impacted by the coronavirus pandemic. In March, the social media giant said it is offering $100 million in cash grants and ad credits for up to 30,000 eligible small businesses.
Follow RTT